Detalhe da pesquisa
1.
Persistent Cancer Cells: The Deadly Survivors.
Cell
; 183(4): 860-874, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186528
2.
Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases.
Cell
; 175(4): 901-902, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30388448
3.
Post-transcriptional polyadenylation site cleavage maintains 3'-end processing upon DNA damage.
EMBO J
; 42(7): e112358, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762421
4.
Cerebral Hemodynamics and Levosimendan Use in Patients with Cerebral Vasospasm and Subarachnoid Hemorrhage: An Observational Perfusion CT-Based Imaging Study.
Neurocrit Care
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38326535
5.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460017
6.
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 24(12): e461-e471, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459873
7.
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet
; 399(10336): 1718-1729, 2022 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367007
8.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877599
9.
Redox activation of ATM enhances GSNOR translation to sustain mitophagy and tolerance to oxidative stress.
EMBO Rep
; 22(1): e50500, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33245190
10.
Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma.
Curr Oncol Rep
; 25(9): 989-996, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37266890
11.
Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series.
J Gastroenterol Hepatol
; 38(12): 2104-2110, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710354
12.
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Future Oncol
; 19(16): 1091-1098, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37309702
13.
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 23(9): 1145-1155, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35940183
14.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
; 23(11): 1378-1388, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265502
15.
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
N Engl J Med
; 381(7): 626-636, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166680
16.
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
J Transl Med
; 20(1): 200, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35538491
17.
Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society.
J Am Acad Dermatol
; 87(3): 551-558, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35104588
18.
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.
Future Oncol
; 18(17): 2041-2051, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35272485
19.
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Lancet Oncol
; 22(3): 370-380, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587894
20.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 848-857, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000246